- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Lunar results show moderate growth
Bone densitometry firm Lunar of Madison, WI, released financial results for its fourth quarter (end-June) that showed a respectable 9% increase in revenue. The company appears to have enjoyed a slightly better quarter than competitor Hologic, which saw
Bone densitometry firm Lunar of Madison, WI, released financial results for its fourth quarter (end-June) that showed a respectable 9% increase in revenue. The company appears to have enjoyed a slightly better quarter than competitor Hologic, which saw its revenues climb only 3%.
For the quarter, Lunar had revenues of $22.2 million, compared with $20.3 million in the fourth quarter of 1996. The company enjoyed net income of $3.6 million, compared with a profit of $3.1 million in the same period of 1996. For the year, Lunar had sales of $81.5 million, up 22% compared with $66.9 million in 1996. The company finished fiscal 1997 with a net profit of $14.3 million, compared with net income of $9.2 million the year before.
Lunar president Dr. Richard Mazess reported that the company is enjoying continued strong demand for its DPIX-IQ x-ray densitometer, particularly in the U.S. The company said that sales of its Artoscan MRI systems and Orca mini-C-arms increased as well, with revenues from both these product lines climbing 42% to $9.1 million for the year.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
